Search clinical trials for: Crenolanib Besylate (CP-868,596-26)
Total 25 results
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid LeukemiaUnited States
-
Arog Pharmaceuticals, Inc.CompletedD842-related Mutant GISTUnited States
-
Arog Pharmaceuticals, Inc.CompletedPhase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsRelapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States
-
Arog Pharmaceuticals, Inc.CompletedRecurrent/Refractory GlioblastomaUnited States
-
Arog Pharmaceuticals, Inc.Terminated
-
St. Jude Children's Research HospitalArog Pharmaceuticals, Inc.; The V Foundation for Cancer ResearchCompletedDiffuse Intrinsic Pontine Glioma | Progressive or Refractory High-Grade GliomaUnited States
-
Arog Pharmaceuticals, Inc.CompletedNewly Diagnosed AML With FLT3 Activating MutationsUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnCarcinoma, Non-Small-Cell Lung
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesUnited States
-
Arog Pharmaceuticals, Inc.AvailableFLT3-ITD Mutation | FLT3/TKD Mutation | PDGFR-Alpha D842V | PDGFRA Gene AmplificationItaly
-
Arog Pharmaceuticals, Inc.Centre Leon Berard; Fox Chase Cancer CenterUnknownGIST With D842V Mutated PDGFRA GeneUnited States, France, Spain, Italy, Germany, Norway, Poland
-
Arog Pharmaceuticals, Inc.CompletedAdvanced Solid TumorsUnited States, Australia
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid LeukemiaUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnRelapsed/Refractory FLT3-mutated AML
-
Arog Pharmaceuticals, Inc.RecruitingNewly Diagnosed FLT3 Mutated AMLUnited States
-
St. Jude Children's Research HospitalOhio State University; Arog Pharmaceuticals, Inc.CompletedAcute Myeloid LeukemiaUnited States
-
Arog Pharmaceuticals, Inc.RecruitingRelapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States, Germany, Spain, Italy, France, Canada
-
National Cancer Institute (NCI)CompletedHilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditionsUnited States
-
Rennes University HospitalCompleted
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupTerminatedRecurrent Non-Small Cell Lung Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Non-Small Cell Lung Cancer AJCC v7United States, Canada
-
University of WashingtonNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Lymphoblastic LymphomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnRecurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T...United States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Lymphoblastic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI); EsPhALL Network/ BFM Study GroupRecruitingAcute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute LeukemiaUnited States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel